z-logo
open-access-imgOpen Access
GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells
Author(s) -
Eric L. Smith,
Kim Harrington,
Mette Stæhr,
Reed Masakayan,
Jon C. Jones,
Thomas J. Long,
Khong Y. Ng,
Majid Ghoddusi,
Terence J. Purdon,
Xiuyan Wang,
Trevor Do,
Minh Thu Pham,
Jessica M. Brown,
Carlos Fernández de Larrea,
Eric J. Olson,
Elizabeth Peguero,
Pei Wang,
Hong Liu,
Yiyang Xu,
Sarah C. Garrett-Thomson,
Steven C. Almo,
HansGuido Wendel,
Isabelle Rivière,
Liu C,
Blythe Sather,
Renier J. Brentjens
Publication year - 2019
Publication title -
science translational medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.819
H-Index - 216
eISSN - 1946-6242
pISSN - 1946-6234
DOI - 10.1126/scitranslmed.aau7746
Subject(s) - multiple myeloma , immunotherapy , medicine , cancer research , immunology , immune system
GPRC5D is an attractive target for immunotherapy of myeloma, and optimized GPRC5D-targeted CAR T cells eradicate myeloma xenografts.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom